Microfluidic enrichment, isolation and characterization of disseminated melanoma cells from lymph node samples.
Autorzy :
Weidele K; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany. Stojanović N; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany. FelicielloG; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany. Markiewicz A; Experimental Medicine and Therapy Research, University of Regensburg, 93053, Regensburg, Germany. Scheitler S; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany. Alberter B; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany. Renner P; Department of Surgery, University Medical Center, 93053, Regensburg, Germany. Haferkamp S; Department of Dermatology, University Hospital Regensburg, 93053, Regensburg, Germany. Klein CA; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany.; Experimental Medicine and Therapy Research, University of Regensburg, 93053, Regensburg, Germany. Polzer B; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany.
Pokaż więcej
Źródło :
International journal of cancer [Int J Cancer] 2019 Jul 01; Vol. 145 (1), pp. 232-241. Date of Electronic Publication: 2019 Jan 14.
Vollmann-Zwerenz A; Department of Neurology and Wilhelm Sander-NeuroOncology Unit, University Hospital Regensburg, 93053 Regensburg, Germany. Leidgens V; Department of Neurology and Wilhelm Sander-NeuroOncology Unit, University Hospital Regensburg, 93053 Regensburg, Germany. FelicielloG; Fraunhofer-Institute for Toxicology and Experimental Medicine, Division of Personalized Tumor Therapy, 93053 Regensburg, Germany. Klein CA; Fraunhofer-Institute for Toxicology and Experimental Medicine, Division of Personalized Tumor Therapy, 93053 Regensburg, Germany.; Experimental Medicine and Therapy Research, University of Regensburg, 93053 Regensburg, Germany. Hau P; Department of Neurology and Wilhelm Sander-NeuroOncology Unit, University Hospital Regensburg, 93053 Regensburg, Germany.
Interleukin-6 trans-signaling is a candidate mechanism to drive progression of human DCCs during clinical latency.
Autorzy :
Werner-Klein M; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany. . Grujovic A; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.; Telexos GmbH, Weilheim, Germany. Irlbeck C; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany. Obradović M; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.; Wellmera AG, Basel, Switzerland. Hoffmann M; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany. Koerkel-Qu H; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany. Lu X; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany. Treitschke S; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany. Köstler C; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany. Botteron C; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany. Weidele K; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany. Werno C; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany. Polzer B; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany. Kirsch S; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany. Gužvić M; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany. Warfsmann J; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany. Honarnejad K; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany. Czyz Z; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany. FelicielloG; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany. Blochberger I; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany. Grunewald S; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany. Schneider E; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany. Haunschild G; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany. Patwary N; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany. Guetter S; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany. Huber S; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany. Rack B; Department OB&GYN and CCCLMU, Breast Center, LMU University Hospital, 80337, Munich, Germany.; Department of Gynecology, Ulm University Hospital, Ulm, Germany. Harbeck N; Department OB&GYN and CCCLMU, Breast Center, LMU University Hospital, 80337, Munich, Germany. Buchholz S; Clinic of Gynecology and Obstetrics, University Medical Center Regensburg, 93053, Regensburg, Germany. Rümmele P; Department of Pathology, University of Regensburg, 93053, Regensburg, Germany.; Institute of Pathology, University Hospital, Friedrich-Alexander-University Erlangen-Nürnberg, 91054, Erlangen, Germany. Heine N; University Center of Plastic-, Aesthetic, Hand- and Reconstructive Surgery, University of Regensburg, Regensburg, Germany. Rose-John S; Institute of Biochemistry, Christian-Albrechts-Universität Kiel, Kiel, Germany. Klein CA; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany. .; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany. .
Pokaż więcej
Źródło :
Nature communications [Nat Commun] 2020 Oct 05; Vol. 11 (1), pp. 4977. Date of Electronic Publication: 2020 Oct 05.
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies
W koszyku znajdują się zamówienia
W koszyku znajdują się zamówienia do wysłania. Czy chcesz wysłać je do realizacji?
